Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
4D Molecular Therapeutics Inc (FDMT)
4D Molecular Therapeutics Inc (FDMT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 527,584
  • Shares Outstanding, K 42,754
  • Annual Sales, $ 3,130 K
  • Annual Income, $ -107,490 K
  • 60-Month Beta 2.47
  • Price/Sales 168.20
  • Price/Cash Flow N/A
  • Price/Book 1.54
Trade FDMT with:

Options Overview Details

View History
  • Implied Volatility 71.32% ( -3.12%)
  • Historical Volatility 60.66%
  • IV Percentile 9%
  • IV Rank 23.92%
  • IV High 144.59% on 04/26/23
  • IV Low 48.29% on 11/14/23
  • Put/Call Vol Ratio 999.99
  • Today's Volume 3
  • Volume Avg (30-Day) 95
  • Put/Call OI Ratio 0.25
  • Today's Open Interest 765
  • Open Int (30-Day) 984

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.68
  • Number of Estimates 4
  • High Estimate -0.41
  • Low Estimate -0.82
  • Prior Year -0.84
  • Growth Rate Est. (year over year) +19.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.73 +26.52%
on 11/10/23
12.60 -2.30%
on 11/20/23
+1.84 (+17.57%)
since 10/27/23
3-Month
9.44 +30.40%
on 10/17/23
17.05 -27.80%
on 08/29/23
-4.53 (-26.90%)
since 08/28/23
52-Week
9.44 +30.40%
on 10/17/23
26.49 -53.53%
on 12/13/22
-11.46 (-48.21%)
since 11/28/22

Most Recent Stories

More News
Astellas and 4D Molecular Therapeutics (4DMT) Enter into License Agreement to Use 4DMT's Proprietary Intravitreal R100 Vector for Rare Ophthalmic Targets

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) (President and CEO: Naoki Okamura, "Astellas") and 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) (CEO: David...

FDMT : 12.31 (-0.24%)
2 Biotech Stocks to Buy, 1 to Sell Now

The biotech industry is well-positioned for long-term growth thanks to increasing demand for quality healthcare, a rapidly aging population, and rising chronic diseases. Therefore, buying fundamentally...

FDMT : 12.31 (-0.24%)
PRQR : 1.3700 (+1.48%)
TRDA : 12.72 (+1.76%)
Markets Today: Stocks Higher as Bond Yields Fall on Jobless Claims Surge

Morning Markets June E-Mini S&P 500 futures (ESM2 3) this morning are up +0.03%, and June Nasdaq 100 E-Mini futures (NQM2 3) are up +0.16%. U.S. stock index futures this morning recovered from overnight...

ESZ23 : 4,568.25 (+0.12%)
NQZ23 : 16,067.25 (+0.12%)
SMTC : 16.40 (+0.12%)
ADBE : 623.32 (+0.65%)
ALV : 100.92 (-0.63%)
IGT : 26.51 (+0.76%)
REVG : 15.33 (unch)
TCOM : 35.40 (-0.34%)
FDMT : 12.31 (-0.24%)
SIG : 81.22 (+0.35%)
OXM : 93.56 (-1.67%)
SMAR : 41.76 (+0.19%)
Stocks Little Changed Before the Open as Investors Weigh Interest Rate Outlook

June S&P 500 futures (ESM23) are up +0.05%, and June Nasdaq 100 E-Mini futures (NQM23) are up +0.15% this morning after three major U.S. benchmark indices finished the regular session mixed as an unexpected...

ESM23 : 4,453.35s (+0.61%)
NQM23 : 15,316.61s (+0.85%)
CPB : 40.44 (-0.96%)
MCHP : 81.82 (+0.07%)
NXPI : 200.03 (+0.19%)
WBD : 10.62 (-1.48%)
WIZZ.LN : 1,848.000 (-1.36%)
GME : 13.49 (+13.27%)
HCP : 21.29 (+1.43%)
EXPI : 12.65 (+3.86%)
CURV : 3.84 (+1.05%)
FDMT : 12.31 (-0.24%)
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates

4D Molecular Therapeutics, Inc. (FDMT) delivered earnings and revenue surprises of 0% and 79.49%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

FDMT : 12.31 (-0.24%)
MRNS : 6.31 (+0.16%)
Spectrum Pharmaceuticals (SPPI) Reports Q1 Loss, Tops Revenue Estimates

Spectrum Pharma (SPPI) delivered earnings and revenue surprises of 60% and 27.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

SPPI : 1.0300 (unch)
FDMT : 12.31 (-0.24%)
4D Molecular Therapeutics, Inc. (FDMT) Soars 11.2%: Is Further Upside Left in the Stock?

4D Molecular Therapeutics, Inc. (FDMT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further...

FDMT : 12.31 (-0.24%)
TBPH : 10.38 (-1.14%)
4D Molecular Therapeutics, Inc. (FDMT) Reports Q4 Loss, Lags Revenue Estimates

4D Molecular Therapeutics, Inc. (FDMT) delivered earnings and revenue surprises of -12% and 74.90%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the...

FDMT : 12.31 (-0.24%)
BVS : 4.01 (-0.50%)
Durect (DRRX) Reports Q4 Loss, Tops Revenue Estimates

Durect (DRRX) delivered earnings and revenue surprises of 13.21% and 2.79%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

DRRX : 0.6230 (-5.46%)
FDMT : 12.31 (-0.24%)
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q4 Loss, Lags Revenue Estimates

Crinetics Pharmaceuticals, Inc. (CRNX) delivered earnings and revenue surprises of -2.44% and 5.47%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for...

CRNX : 31.35 (-1.45%)
FDMT : 12.31 (-0.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

4D Molecular Therapeutics Inc. is a clinical-stage gene therapy company which develops product candidates using its targeted and evolved adeno-associated viruses vectors. It offers a portfolio of gene therapy product candidates focusing on the ophthalmology, cardiology and pulmonology therapeutic areas....

See More

Key Turning Points

3rd Resistance Point 12.89
2nd Resistance Point 12.62
1st Resistance Point 12.47
Last Price 12.31
1st Support Level 12.05
2nd Support Level 11.78
3rd Support Level 11.63

See More

52-Week High 26.49
Fibonacci 61.8% 19.98
Fibonacci 50% 17.97
Fibonacci 38.2% 15.95
Last Price 12.31
52-Week Low 9.44

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar